Question · Q4 2025
Joseph Ritchie sought clarification on the Q1 2026 EBITDA outlook, considering Paragon's accretion and seasonality. He also asked about Mirion's commercial performance and win rates for the $400 million large project pipeline, and the expected incremental margin for the medical business in 2026.
Answer
CFO Brian Schopfer explained that Q1 2026 would be the lightest quarter for both Mirion and Paragon, with margin contraction due to Paragon's dilutive impact and lower sensing business volume. CEO Thomas Logan highlighted Paragon and Certrec's impact on customer intimacy and commercial traction, expecting improved win rates. Brian Schopfer anticipated strong but not as high margin expansion for medical in 2026 compared to 2025.
Ask follow-up questions
Fintool can predict
MIR's earnings beat/miss a week before the call


